Identification of the AMPK/ACC/SREBP1 axis as a key regulatory pathway underlying rhein’s effects underscores its translational relevance and positions it as a promising pharmacological candidate for NAFLD therapy. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.